Table 3.
Patient and HIPEC characteristics
| Parameter | N (%) |
|---|---|
| HIPEC mode | 153 (97.5%) |
| HIPEC | 121 (77%) |
| HIPEC + EPIC | 36 (23%) |
| Gender | |
| Male | 65 (41.4%) |
| Female | 92 (58.6%) |
| Age (years) | 58 ± 12.6 |
| BMI (kg/m2) | 26 ± 5.6 |
| Neoadjuvant therapy | 60 (38.2%) |
| Hospital time (days) | 21.7 ± 13.1 |
| ICU/IMC time (days) | 7.1 ± 7.4 |
| Primary tumor | |
| Colorectal | 52 (33.1%) |
| Appendiceal | 47 (29.9%) |
| Gastric | 27 (17.2%) |
| Mesothelium | 14 (8.9%) |
| Ovarian | 12 (7.7%) |
| Intestine | 4 (2.5%) |
| CUP | 1 (0.6%) |
| Postop. complications | |
| Acute kidney injury | 50 (31.8%) |
| Leucopenia | 28 (17.8%) |
| Abscess | 4 (2.5%) |
| Fistula* | 4 (2.5%) |
| Pancreatic fistula | 3 (1.9%) |
| Anastomotic leakage | 11 (7%) |
| Perforation** | 6 (3.8%) |
| 30-Day mortality | 2 (1.27%) |
HIPEC, hyperthermic intraperitoneal chemotherapy, EPIC early postoperative intraperitoneal chemotherapy, BMI body mass index, ICU intensive care unit, IMC intermediate care unit, CUP carcinoma of unknown primary
*Enteroatmospheric, enterocolic, vesicorectal, gastropleural fistula
**Intestinal, bladder perforation